Global Antibody Drug Conjugate Market is valued at approximately USD 5.60 billion in 2023 and is anticipated to grow with a healthy growth rate of more than 16.12% over the forecast period 2024-2030.

A new study shows that racial and ethnic disparities among Medicare beneficiaries who receive ERBB2 (formerly HER2)-targeted therapies for breast cancer have narrowed significantly from 2010 to ...

Discover which therapies are expected to grab the HER2-low cancers market share @ HER2-low Cancers Market Report The HER2-low ...

The tyrosine kinase receptor ERBB2/HER2 is amplified in a significant proportion of human breast cancers, where it is correlated to poor prognosis for the patient. Due to its central role in the ...

Biomarker data from CodeBreaK 300 suggest DNA and RTK pathway alterations may underlie resistance to sotorasib plus ...